covid-19 covance labcorp diagnostics drug development

Covance and LabCorp deliver unmatched COVID-19 diagnostic and therapeutic applications

We’re in this together: How Covance and LabCorp are delivering unmatched acceleration of COVID-19 diagnostic and therapeutic applications Accelerating much needed COVID-19 testing, vaccines and treatment options across the world can’t be done alone. We’re in this together and ready to apply our unique combination of solutions that blend Covance …

LabCorp expands drug development solutions with acquisition of Sciformix

Sciformix extends Covance’s pharmacovigilance capabilities for post-approval safety solutionsBURLINGTON, N.C.–(BUSINESS WIRE)–Jun. 11, 2018– LabCorp® (NYSE: LH), a leading global life sciences company, announced today that it has acquired Sciformix Corporation, a scientific process outsourcing company focused on pharmacovigilance and regulatory solutions for biopharmaceutical and medical devices clients. Sciformix will become …

Diabetic Kidney Disease Studies

Leveraging Real-World Patient Data to Support Recruitment in Diabetic Kidney Disease Studies

Practicing physicians frequently obtain laboratory assessments of kidney function in their routine management of patients with diabetes. Two tests that are commonly performed are the estimated glomerular filtration rate (eGFR) and the urinary albumin to creatinine ratio (ACR). Results of these tests are often used to determine patient eligibility for …